Item 1.01
|
Entry into a Material Definitive Agreement.
|
Asset
Purchase Agreement for the Sale of OMIDRIA® Franchise
On December 1, 2021, Omeros Corporation (the “Company”)
entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Rayner Surgical Inc. (the “Purchaser”)
and Rayner Surgical Group Limited, as parent guarantor, pursuant to which the Company agreed to sell, and the Purchaser agreed to purchase,
certain assets and liabilities related to the Company’s commercial product, OMIDRIA® (phenylephrine and ketorolac
intraocular solution) 1% / 0.3%. The transaction contemplated by the Asset Purchase Agreement (the “Transaction”) will close
upon the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting or suspension
period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and any other applicable competition laws.
The Company will receive an upfront payment at
closing of $125.0 million, subject to certain adjustments for inventory, fees, prepaid items and expenses. The Company will receive a
royalty of 50% of the net revenue, as defined in the Asset Purchase Agreement, from sales of OMIDRIA in the United States between the
closing date and the earlier of January 1, 2025 or the payment of the $200.0 million milestone described below. After such date the Company
will receive a royalty of 30% of the net revenue from sales of OMIDRIA in the United States until the expiration or termination of the
last issued and unexpired patent with respect to OMIDRIA in the United States. The United States royalty rate is subject to reduction
upon the occurrence of certain events described in the Asset Purchase Agreement, including during any period in which OMIDRIA is no longer
eligible for separate payment. The Company also will receive a royalty of 15% of the net revenue from sales of OMIDRIA outside the United
States on a country-by-country basis between the closing date and the expiration or termination of the last issued and unexpired patent
with respect to OMIDRIA in such country. In addition, the Company will receive a $200.0 million milestone payment if, prior to January
1, 2025, separate payment for OMIDRIA is secured for a continuous period of at least four years. The Company will continue to receive
revenues from, and incur expenses in connection with, the sale of OMIDRIA prior to the closing date, and will retain accounts receivable
from sales prior to the closing date.
The Asset Purchase Agreement contains customary
representations, warranties, covenants and indemnification obligations. The Asset Purchase Agreement may be terminated by mutual written
consent or by either party, prior to the closing, for an uncured material breach of the Asset Purchase Agreement by the other party, if
the closing does not occur within 120 days following the execution date, or if the consummation of the Transaction would violate any non-appealable
final order, decree or judgment of an applicable governmental authority.
The foregoing is a brief description of the material
terms of the Asset Purchase Agreement and does not purport to be complete description of the rights and obligations of the parties thereunder.
A copy of the Asset Purchase Agreement will be filed as an exhibit to a future periodic or current report. The Asset Purchase Agreement
contains representations, warranties and covenants that were made only for purposes of such agreement and as of specific dates, are solely
for the benefit of the parties to thereto, and may be subject to limitations agreed upon by such parties. The Asset Purchase Agreement
is not intended to provide any other factual information about the Company.
Amendment to Loan and Security Agreement
In connection with the execution of the Asset Purchase
Agreement, on December 1, 2021 the Company and Silicon Valley Bank (“SVB”) entered into a Consent and Second Amendment (the
“Second Amendment”) to the Loan and Security Agreement, dated as of August 2, 2019. Pursuant to the Second Amendment, SVB
provided its consent to the Transaction and release of liens with respect to the transferred assets. In addition, the Second Amendment
revises the original Loan and Security Agreement to provide that the borrowing base will include 85% of eligible monthly royalty payments,
including those from the Purchaser and its affiliates, less applicable discounts, credits and other offsets. Under the terms of the Second
Amendment, the Company will continue to be eligible to draw, on a revolving basis, up to the lesser of $50.0 million or 85% of eligible
accounts receivable and eligible monthly royalty payments, less certain reserves, and the agreement will mature on August 2, 2022.
The foregoing is a brief description of the
material terms of the Second Amendment and does not purport to be complete description of the rights and obligations of the parties
thereunder. A copy of the Second Amendment will be filed as an exhibit to a future periodic or current report. The Second Amendment
contains representations, warranties and covenants that were made only for purposes of such agreement and as of specific dates, are
solely for the benefit of the parties to thereto, and may be subject to limitations agreed upon by such parties. The Second
Amendment is not intended to provide any other factual information about the Company.